Development of an economic model to assess the cost-effectiveness of hawthorn extract as an adjunct treatment for heart failure in Australia

Ford, Emily, Adams, Jon and Graves, Nicholas (2012) Development of an economic model to assess the cost-effectiveness of hawthorn extract as an adjunct treatment for heart failure in Australia. BMJ Open, 2 5: e001094.1-e001094.11. doi:10.1136/bmjopen-2012-001094

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ288420_peer_review.pdf HERDC evidence - not publicly available application/pdf 53.5KB 0

Author Ford, Emily
Adams, Jon
Graves, Nicholas
Title Development of an economic model to assess the cost-effectiveness of hawthorn extract as an adjunct treatment for heart failure in Australia
Journal name BMJ Open
ISSN 2044-6055
Publication date 2012-09-01
Sub-type Article (original research)
DOI 10.1136/bmjopen-2012-001094
Open Access Status DOI
Volume 2
Issue 5
Start page e001094.1
End page e001094.11
Total pages 11
Place of publication London, United Kingdom
Publisher B M J
Collection year 2013
Language eng
Formatted abstract
Objective: An economic model was developed to evaluate the cost-effectiveness of hawthorn extract as an adjunctive treatment for heart failure in Australia.

Methods: A Markov model of chronic heart failure was developed to compare the costs and outcomes of standard treatment and standard treatment with hawthorn extract. Health states were defined by the New York Heart Association (NYHA) classification system and death. For any given cycle, patients could remain in the same NYHA class, experience an improvement or deterioration in NYHA class, be hospitalised or die. Model inputs were derived from the published medical literature, and the output was quality-adjusted life years (QALYs). Probabilistic sensitivity analysis was conducted. The expected value of perfect information (EVPI) and the expected value of partial perfect information (EVPPI) were conducted to establish the value of further research and the ideal target for such research.

Results: Hawthorn extract increased costs by $1866.78 and resulted in a gain of 0.02 QALYs. The incremental cost-effectiveness ratio was $85 160.33 per QALY. The cost-effectiveness acceptability curve indicated that at a threshold of $40 000 the new treatment had a 0.29 probability of being cost-effective. The average incremental net monetary benefit (NMB) was -$1791.64, the average NMB for the standard treatment was $92 067.49, and for hawthorn extract $90 275.84. Additional research is potentially costeffective if research is not proposed to cost more than $325 million. Utilities form the most important target parameter group for further research.

Conclusions: Hawthorn extract is not currently considered to be cost-effective in as an adjunctive treatment for heart failure in Australia. Further research in the area of utilities is warranted.
Keyword Hawthorn extract
Heart failure
Economic model
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Article number e001094

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2013 Collection
School of Public Health Publications
School of Social Science Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 7 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 9 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 08 Jan 2013, 10:10:05 EST by Geraldine Fitzgerald on behalf of School of Public Health